The study found a combination of anti-HER2.CAR/NK-92 cell therapy and HER2-AAV anti-PD−1 effectively controlled tumor growth and extended survival in both subcutaneous GL261-HER2 and Tu2449-HER2 glioma models. This evidence concerns the gene ERBB2 and central nervous system cancer.